Moderna, Inc. $MRNA Shares Purchased by Czech National Bank

Czech National Bank raised its holdings in Moderna, Inc. (NASDAQ:MRNA) by 7.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 83,189 shares of the company’s stock after purchasing an additional 5,409 shares during the period. Czech National Bank’s holdings in Moderna were worth $2,295,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. S Bank Fund Management Ltd purchased a new stake in shares of Moderna during the first quarter worth about $25,000. SVB Wealth LLC acquired a new stake in Moderna in the 1st quarter worth about $28,000. Costello Asset Management INC purchased a new stake in Moderna during the 1st quarter worth approximately $30,000. Sentry Investment Management LLC purchased a new stake in Moderna during the 1st quarter worth approximately $31,000. Finally, Deseret Mutual Benefit Administrators raised its holdings in shares of Moderna by 53.3% during the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company’s stock valued at $32,000 after acquiring an additional 392 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on MRNA shares. Barclays dropped their price target on Moderna from $40.00 to $31.00 and set an “equal weight” rating for the company in a research report on Monday, August 4th. Bank of America dropped their target price on Moderna from $26.00 to $25.00 and set an “underperform” rating for the company in a report on Tuesday, July 22nd. Citigroup began coverage on Moderna in a report on Friday, August 1st. They set a “neutral” rating and a $40.00 price target on the stock. Evercore ISI set a $32.00 price target on shares of Moderna in a research report on Friday, August 1st. Finally, Morgan Stanley reissued an “equal weight” rating and set a $32.00 target price on shares of Moderna in a research note on Friday, August 1st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, fourteen have issued a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $41.81.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $25.24 on Friday. The business has a 50-day moving average of $27.57 and a 200-day moving average of $27.99. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $67.96. The stock has a market capitalization of $9.82 billion, a price-to-earnings ratio of -3.35 and a beta of 1.93.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.Moderna’s quarterly revenue was down 41.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.